Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoembolisation with idarubicin-loaded microspheres in hepatocellular carcinoma not eligible for curative treatment
2014-000050-10Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- May 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idarubicin in hepatocellular carcinoma (HCC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoints: Objective response rate (central review) at 6 months and Central MRI review at 6 months. Started May 2014; status: completed.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2014-000050-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000050-10.